- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03062475
Lifestyle Intervention to Prevent the Recurrence of Gestational Diabetes Mellitus
The Efficacy of Lifestyle Intervention in Preventing the the Recurrence of Gestational Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chen Wang
- Phone Number: 18518079870
- Email: kisskissy22@126.com
Study Contact Backup
- Name: Yumei Wei
- Phone Number: 18601369529
- Email: weiyumei1982@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Chen Wang
- Phone Number: 18518079870
- Email: kisskissy22@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singleton;
- non-smoking ;
- before 12+6 weeks gestation.
Exclusion Criteria:
- less than 18 years old;
- unwilling to provide informed consent;
- cervical insufficiency;
- women on any medication for pre-existing hypertension, diabetes, cardiac disease, renal disease, systemic lupus erythematosus, thyroid disease or psychosis;
- women who were currently being treated with metformin or corticosteroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: lifestyle intervention group
Pregnant women allocated to this group receive lifestyle intervention.
With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.
With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
|
With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy. |
No Intervention: control group
Pregnant women allocated to this group receive standard prenatal care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GDM
Time Frame: 24-28 gestational weeks
|
According to the new criteria amended in August 2014 in China, GDM was diagnosed when any one value reaches or exceeds 5.1 mmol/L at 0 hours, 10.0 mmol/L at 1 hour, or 8.5 mmol/L at 2 hours.
Values of 7.0 mmol/L at 0 hours or 11.1 mmol/L at 2 hours were diagnosed as DM, regardless of the pregnancy stage
|
24-28 gestational weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
birth weight
Time Frame: up to 43 gestational weeks
|
birth weight measured after baby was delivered and accurate to 0.1 kg
|
up to 43 gestational weeks
|
gestational weeks
Time Frame: up to 43 gestational weeks
|
record the gestational weeks for delivery
|
up to 43 gestational weeks
|
delivery mode
Time Frame: up to 43 gestational weeks
|
this includes vaginal delivery, operative vaginal delivery or cesarean delivery
|
up to 43 gestational weeks
|
macrosomia
Time Frame: up to 43 gestational weeks
|
birth weight above 4000.0 g
|
up to 43 gestational weeks
|
LGA
Time Frame: up to 43 gestational weeks
|
birth weight above the 90th percentile for gestational age
|
up to 43 gestational weeks
|
SGA
Time Frame: up to 43 gestational weeks
|
birth weight below the 10th percentile for gestational age
|
up to 43 gestational weeks
|
gestational hypertention
Time Frame: up to 43 gestational weeks
|
defined as blood pressure elevation [systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg] after 20 weeks gestation in the absence of proteinuria
|
up to 43 gestational weeks
|
pre-eclampsia
Time Frame: up to 43 gestational weeks
|
defined as new-onset hypertension [systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg] and new-onset proteinuria [300 mg of protein in 24 hours or a urine protein/creatinine ratio of 0.3 mg/dL] after 20 weeks gestation or, in the absence of proteinuria, new-onset hypertension with new-onset thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral or visual disturbances
|
up to 43 gestational weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Huixia Yang, Peking Unviersity First Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20170226
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes Mellitus (GDM)
-
Hospital Arnau de VilanovaCompletedGestational Diabetes Mellitus (GDM)Spain
-
Federal State Budgetary Institution, V. A. Almazov...RecruitingGestational Diabetes Mellitus (GDM)Russian Federation
-
Tianjin Women and Children's Health CenterUnknownGestational Diabetes Mellitus (GDM)China
-
Qingdao UniversityUnknownPregnancy | Type 2 Diabetes | Gestational Diabetes Mellitus (GDM)
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Rabin Medical CenterUnknown
-
Peking Union Medical College HospitalBeijing Chao Yang Hospital; Beijing Obstetrics and Gynecology Hospital; San MediTech(Huzhou)Co... and other collaboratorsUnknownSANZ®KINGWILL Combined With CGM Equipment in GDM Patients | GLUCERNA SR® Combined With CGM Equipment in GDM PatientsChina
-
Kayseri Education and Research HospitalCompletedRetinal Evaluation in Patients With GDM.Turkey
-
G. d'Annunzio UniversityUniversity of ChietiUnknown
-
Min ShangEnrolling by invitation
Clinical Trials on lifestyle intervention with dietary and exercise recommendation
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive BladderTurkey
-
SingHealth PolyclinicsNational University Hospital, Singapore; Khoo Teck Puat Hospital; Singapore General... and other collaboratorsTerminatedDiabetes Mellitus, Type 2 | Insulin Resistance | Mild Cognitive ImpairmentSingapore
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Federico II University; IRCCS Cancer Referral Center of Basilicata; European... and other collaboratorsCompletedBreast Cancer Invasive
-
University of OtagoEdgar National Centre for Diabetes ResearchCompletedObesity | Type 2 Diabetes MellitusNew Zealand
-
Rabin Medical CenterClalit Health ServicesCompleted
-
Hubei Hospital of Traditional Chinese MedicineShanxi Provincial Hospital of Traditional Chinese Medicine; Wuhan Hospital... and other collaboratorsUnknown
-
Hvidovre University HospitalCompleted
-
University of Southern DenmarkCompletedInflammatory Bowel DiseasesDenmark
-
University of Lausanne HospitalsCompletedGestational Diabetes MellitusSwitzerland
-
Oregon Health and Science UniversityCompleted